GEVA has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Synageva BioPharma Corp's quarterly additional paid-in capital increased from Jun. 2014 ($901.54 Mil) to Sep. 2014 ($908.90 Mil) and increased from Sep. 2014 ($908.90 Mil) to Dec. 2014 ($920.33 Mil).
Synageva BioPharma Corp's annual additional paid-in capital increased from Dec. 2012 ($388.94 Mil) to Dec. 2013 ($684.47 Mil) and increased from Dec. 2013 ($684.47 Mil) to Dec. 2014 ($920.33 Mil).
Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.
Additional Paid-In Capital is calculated as
|Additional Paid-In Capital||=||(Issue Price||-||Par Value)||*||Shares Outstanding|
* All numbers are in millions except for per share data and ratio. All numbers are in their own currency.
Synageva BioPharma Corp Annual Data
Synageva BioPharma Corp Quarterly Data
Disclaimers: GuruFocus.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The gurus may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.